308 related articles for article (PubMed ID: 8726359)
1. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
2. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP.
Puri RN; Kumar A; Chen H; Colman RF; Colman RW
J Biol Chem; 1995 Oct; 270(41):24482-8. PubMed ID: 7592664
[TBL] [Abstract][Full Text] [Related]
4. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets.
Puri RN; Zhou F; Hu CJ; Colman RF; Colman RW
Blood; 1991 Feb; 77(3):500-7. PubMed ID: 1846761
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence for covalent modification of cysteine and lysine residues.
Puri RN; Colman RW
Arch Biochem Biophys; 1991 May; 286(2):419-27. PubMed ID: 1910292
[TBL] [Abstract][Full Text] [Related]
7. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3'-sulfonate (Woodward's reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor.
Puri RN; Colman RW
Anal Biochem; 1996 Sep; 240(2):251-61. PubMed ID: 8811919
[TBL] [Abstract][Full Text] [Related]
8. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
9. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets.
Soslau G; McKenzie RJ; Brodsky I; Devlin TM
Biochim Biophys Acta; 1995 Jul; 1268(1):73-80. PubMed ID: 7626665
[TBL] [Abstract][Full Text] [Related]
10. Aggregin: a platelet ADP receptor that mediates activation.
Colman RW
FASEB J; 1990 Mar; 4(5):1425-35. PubMed ID: 2407587
[TBL] [Abstract][Full Text] [Related]
11. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
Krishnamurthi S; Joseph S; Kakkar VV
Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.
Cattaneo M; Lecchi A; Randi AM; McGregor JL; Mannucci PM
Blood; 1992 Dec; 80(11):2787-96. PubMed ID: 1333302
[TBL] [Abstract][Full Text] [Related]
13. Activation of the cloned platelet thrombin receptor decreases the pertussis-toxin-dependent ADP-ribosylation of the membrane and soluble inhibitory guanine-nucleotide-binding-alpha proteins. Inhibition by the prostacyclin analog, iloprost.
Wilhelm B; Siess W
Eur J Biochem; 1993 Aug; 216(1):81-8. PubMed ID: 7689967
[TBL] [Abstract][Full Text] [Related]
14. Activation of human platelets by N-substituted aminophospholipids.
Martin TW; Joist JH; Bauman JE; Lagunoff D
J Biol Chem; 1985 Mar; 260(5):2852-6. PubMed ID: 2982840
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of collagen-induced platelet activation by 5'-p-fluorosulfonylbenzoyl adenosine: evidence for an adenosine diphosphate requirement and synergistic influence of prostaglandin endoperoxides.
Colman RW; Figures WR; Scearce LM; Strimpler AM; Zhou FX; Rao AK
Blood; 1986 Aug; 68(2):565-70. PubMed ID: 3730618
[TBL] [Abstract][Full Text] [Related]
17. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane.
DiMinno G; Silver MJ; Cerbone AM; Riccardi G; Rivellese A; Mancini M; Thiagarajan P
Blood; 1985 Jan; 65(1):156-62. PubMed ID: 2981130
[TBL] [Abstract][Full Text] [Related]
18. Aggregation of human and canine platelets: modulation by purine nucleotides.
Soslau G; Arabe L; Parker J; Pelleg A
Thromb Res; 1993 Oct; 72(2):127-37. PubMed ID: 8303650
[TBL] [Abstract][Full Text] [Related]
19. Platelet lysis and functional perturbation by 13-methyl myristate. The major fatty acid in Flavobacterium ranacida.
Faung ST; Chiu L; Wang CT
Thromb Res; 1996 Jan; 81(1):91-100. PubMed ID: 8747524
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
